257 results
8-K
EX-99.1
LLY
Lilly(Eli) & Co
30 Apr 24
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
7:04am
trial, which evaluated the efficacy and safety of donanemab in early symptomatic Alzheimer's disease;
The announcement that the multi-dose Kwikpen … pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; safety or efficacy concerns
424B2
pixz50z6lstbmdaf
8 Feb 24
Prospectus for primary offering
4:51pm
424B2
43lhp0u 9ejq1x9
7 Feb 24
Prospectus for primary offering
8:12am
8-K
EX-99.1
i76z5p6865ofi
6 Feb 24
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
7:04am
8-K
EX-99.1
ai5izb5
2 Nov 23
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
7:02am
CORRESP
uwnkebdr43dzvauic
26 Oct 23
Correspondence with SEC
12:00am
UPLOAD
wxyc6fwi
29 Sep 23
Letter from SEC
12:00am
CORRESP
yb8gvmq6nk
20 Sep 23
Correspondence with SEC
12:00am
8-K
EX-99.1
iwseesfhhbqga8mp
8 Aug 23
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
7:01am
SC TO-T
EX-99
fkuenq2fh dnxsbugyf
13 Jul 23
Third party tender offer statement
8:01am
8-K
EX-99.01
52r8 8w5u
27 Apr 23
Results of Operations and Financial Condition
7:02am
PX14A6G
w0qqa0uifm013rfc 68
10 Apr 23
Letter to shareholders
4:51pm
8-K
EX-99
jgbepfcj4404
13 Dec 22
Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines
7:03am